Roche reported Phase 3 data showing its oral selective estrogen receptor degrader (SERD) giredestrant reduced risk of progression in ER-positive, HER2-negative breast cancer patients, including those without ESR1 mutations. The detailed presentation revealed giredestrant delivered significant improvement in progression-free survival versus standard care in both the intention-to-treat population and an ESR1-mutant subgroup. Additional trial results presented at ESMO reinforced Roche’s claim that the pill could distinguish itself within a crowded field of hormone-degrading agents. Company officials emphasized immature overall survival data and ongoing analyses; regulators will assess whether efficacy across non-mutant patients supports broad labeling. Investors and competitors will watch follow-up endpoints and safety profiles closely as Roche positions the pill across metastatic and earlier settings.